Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

The mTOR Inhibitor RAD001 (everolimus) Is Active Against Multiple Myeloma Cells In Vitro and in Vivo.

Nicholas Mitsiades, MD, PhD, Ciaran McMullan, MSc, Vassiliki Poulaki, MD, PhD, Joseph Negri, Noopur Raje, MD, Shaji Kumar, MD, Despoina Sikoutri, Teru Hideshima, MD, PhD, Dharminder Chauhan, PhD, Paul G. Richardson, MD, Robert L. Schlossman, MD, Andrew L. Kung, MD, PhD, Heidi Lane, PhD, Nikhil C. Munshi, MD, PhD, Kenneth C. Anderson, MD, Constantine S. Mitsiades, MD, PhD

Blood (2004) 104 (11): 1496.

https://doi.org/10.1182/blood.V104.11.1496.1496

Published: 2004

Journal Articles

Phase I Clinical Trial of Oral Administration of the Histone Deacetylase (HDAC) Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) in Patients with Relapsed/Refractory Multiple Myeloma (MM).

Blood (2004) 104 (11): 1503.

https://doi.org/10.1182/blood.V104.11.1503.1503

Published: 2004

Journal Articles

Evaluation of the Ras/B-Raf/SHP-2 Axis in B Cell Malignancies.

Constantine S. Mitsiades, MD, PhD, Nicholas Mitsiades, MD, PhD, Galinos Fanourakis, BSc, Athina Goudopoulou, BSc, Ciaran J. McMullan, MSc, Gerasimos Voutsinas, PhD, Nikhil C. Munshi, MD, PhD, Kenneth C. Anderson, MD

Blood (2004) 104 (11): 4344.

https://doi.org/10.1182/blood.V104.11.4344.4344

Published: 2004

Journal Articles

NVP-AEW541: A Selective Small Molecule IGF-1R Tyrosine Kinase Inhibitor Is Active Against Multiple Myeloma and Other Hematologic Neoplasias and Solid Tumors.

Nicholas Mitsiades, MD, PhD, Ciaran J. McMullan, Vassiliki Poulaki, MD, PhD, Reshma Shringarpure, PhD, Towia A. Libermann, PhD, Teru Hideshima, MD, PhD, Dharminder Chauhan, PhD, Robert L. Schlossman, MD, Paul G. Richardson, MD, Nikhil C. Munshi, MD, PhD, Carlos Garcia-Echeverria, PhD, Francesco Hoffmann, PhD, Kenneth C. Anderson, MD, Constantine S. Mitsiades, MD, PhD

Blood (2004) 104 (11): 766.

https://doi.org/10.1182/blood.V104.11.766.766

Published: 2004

Journal Articles

IPI-504: A Novel hsp90 Inhibitor with In Vitro and In Vivo Anti-Tumor Activity.

Constantine S. Mitsiades, MD, PhD, Nicholas Mitsiades, MD, PhD, Melissa Rooney, Joseph Negri, Corey C. Geer, MSc, Melissa Pink, Christine Pien, Teru Hideshima, MD, PhD, Dharminder Chauhan, PhD, Nikhil C. Munshi, MD, PhD, Paul G. Richardson, MD, John Barrett, PhD, Jeffrey K. Tong, PhD, David Grayzel, Vito Palombella, PhD, Julian Adams, PhD, Kenneth C. Anderson, MD

Blood (2004) 104 (11): 2403.

https://doi.org/10.1182/blood.V104.11.2403.2403

Published: 2004

Journal Articles

Anti-Tumor Activity of KOS-953, a Cremophor-Based Formulation of the hsp90 Inhibitor 17-AAG.

Constantine S. Mitsiades, MD, PhD, Nicholas Mitsiades, MD, PhD, Melissa Rooney, Teru Hideshima, MD, PhD, Dharminder Chauhan, PhD, Nikhil C. Munshi, MD, PhD, Robert Johnson, MD, Alison Hannah, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD

Blood (2004) 104 (11): 2404.

https://doi.org/10.1182/blood.V104.11.2404.2404

Published: 2004

Journal Articles

Avicins: A Novel Class of Anti-Myeloma Agents.

Nicholas Mitsiades, MD, PhD, Ciaran J. McMullan, MSc, Vassiliki Poulaki, MD, PhD, Joseph Negri, David C. Geer, MSc, Valsala Haridas, PhD, Nikhil C. Munshi, MD, PhD, Jordan Gutterman, MD, Kenneth C. Anderson, MD, Constantine S. Mitsiades, MD, PhD

Blood (2004) 104 (11): 3405.

https://doi.org/10.1182/blood.V104.11.3405.3405

Published: 2004

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

The mTOR Inhibitor RAD001 (everolimus) Is Active Against Multiple Myeloma Cells In Vitro and in Vivo.

Phase I Clinical Trial of Oral Administration of the Histone Deacetylase (HDAC) Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) in Patients with Relapsed/Refractory Multiple Myeloma (MM).

Evaluation of the Ras/B-Raf/SHP-2 Axis in B Cell Malignancies.

NVP-AEW541: A Selective Small Molecule IGF-1R Tyrosine Kinase Inhibitor Is Active Against Multiple Myeloma and Other Hematologic Neoplasias and Solid Tumors.

IPI-504: A Novel hsp90 Inhibitor with In Vitro and In Vivo Anti-Tumor Activity.

Anti-Tumor Activity of KOS-953, a Cremophor-Based Formulation of the hsp90 Inhibitor 17-AAG.

Avicins: A Novel Class of Anti-Myeloma Agents.

Email alerts

ASH Publications

American Society of Hematology

Update search

The mTOR Inhibitor RAD001 (everolimus) Is Active Against Multiple Myeloma Cells In Vitro and in Vivo.

Phase I Clinical Trial of Oral Administration of the Histone Deacetylase (HDAC) Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) in Patients with Relapsed/Refractory Multiple Myeloma (MM).

Evaluation of the Ras/B-Raf/SHP-2 Axis in B Cell Malignancies.

NVP-AEW541: A Selective Small Molecule IGF-1R Tyrosine Kinase Inhibitor Is Active Against Multiple Myeloma and Other Hematologic Neoplasias and Solid Tumors.

IPI-504: A Novel hsp90 Inhibitor with In Vitro and In Vivo Anti-Tumor Activity.

Anti-Tumor Activity of KOS-953, a Cremophor-Based Formulation of the hsp90 Inhibitor 17-AAG.

Avicins: A Novel Class of Anti-Myeloma Agents.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only